Navigation Links
Gentag, Inc. and MacroArray Technologies Join Forces
Date:6/9/2008

WASHINGTON, June 9 /PRNewswire/ -- Gentag, Inc. and MacroArray Technologies, LLC have entered into a development program to design a wireless immunoassay incorporating Gentag's cell phone communication technology and MacroArray's urine diagnostic test for prostate cancer.

One in six males are at risk of developing prostate cancer, but unfortunately not all men are being tested. In order to simplify and expand the use of low cost wireless diagnostic assays for early cancer detection, Gentag, Inc. and MacroArray Technologies have teamed to develop a new wireless test platform that will incorporate Gentag's cell phone-sensor technology with MacroArray's proteomics discovery technology to create a series of new, patient friendly, disposable, wireless diagnostic tests. The first of these will be a test for prostate cancer based on MacroArray's proprietary reagents.

Similar to the currently available pregnancy strip test, men will place a urine sample on the test strip that incorporates an imbedded wireless sensor tag. The antibodies in the strip test will react with the antigens in the urine, the resulting data will be sensed by the imbedded electronic tag and communicated to a cell phone or PDA that will process the data and transmit the results to the attending physician.

During the past year, approximately 60 million PSA tests were performed worldwide and over 200,000 men were diagnosed with prostate cancer. Nearly 35,000 will die each year from the disease. It is hoped that the availability of a simple low cost urine-based test will increase the number of men who evaluate their prostate health on a regular basis.

"The proprietary technology from Gentag combined with MacroArray's biomarkers will provide a significant level of exclusivity in this market," commented Dr. John Peeters, CEO of Gentag. "The combination of our two companies will dramatically expand the utility of our diagnostic tests," commented Mr. Mike Wassil, CEO of MacroArray.

About MacroArray Technologies

MacroArray Technologies is a theranostics company with a proprietary proteomics discovery platform that provides the rapid ability to identify novel biomarkers for diseases such as cancer. Their goal is to provide products for early detection leading to better medical and economic outcomes. The company has a number of tests in development including the Pre-Malignant Prostate cancer and an early stage biomarker for colon cancer.

About Gentag, Inc.

Gentag, Inc. is a technology development company focusing on innovative, low-cost, wireless sensor network technologies based on cell phones. The company owns unique intellectual property relating to cell phone-sensor combinations and wireless sensor networks, including patents 7,109,859 and 7,148,803. The effective combination of cell phone reader technology with a disposable sensor platform has led to a variety of medical diagnostic applications providing consumers, physicians, and various industries with instant access to vital information over established wireless networks, the Internet, and client-specific databases. The company is the recipient of the 2008 North American Technology Innovation Award from Frost & Sullivan.

For inquiries, please contact Marc Onigman at (617)-413-2830. For licensing or investment opportunities please contact Mr. Tom Stagnaro at tom.stagnaro@gentag.com.

For more information, visit:

http://www.gentag.com/

http://www.macroarraytechnologies.com/


'/>"/>
SOURCE Gentag, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Dr. Edward Hebert is celebrating ... imagine doing anything else,” said Dr. Hebert. “I count my blessings daily for the ... with my patients is what I look forward to the most. The relationships I ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Grandpa's Visit”: a tender and ... share with the others. “Grandpa's Visit” is the creation of published author, Beverly Brumfield, ... is much like the character in her book. She shares, “Mr. Rice is struggling ...
(Date:9/25/2017)... ... , ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the ... drinks, with the new NEXTY Gold Award at the Natural Products Expo East trade ... which is reserved for just those companies that hit high marks on the criteria ...
(Date:9/25/2017)... ... September 25, 2017 , ... Emerald Ash Borers kill Ash trees in as ... throughout the Philadelphia region. A video by Rob Nagy, ISA Certified Arborist at Giroud ... While several are dead or showing signs of decline from Emerald Ash Borers, two ...
(Date:9/24/2017)... ... ... Andrea Purcell, NMD, had an epiphany one evening. Four months pregnant, she sat sobbing at ... pregnancy was so hard. She wondered why no one talks about what it is really ... she decided to write what she wished her friends and colleagues could have told her: ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s annual ... guide to the latest innovations happening across the industry. ... publication to focus on providing a comprehensive look at ... issue covers the most innovative companies, startups, divisions, products, ... "Everyone in this industry wants ...
Breaking Medicine Technology: